Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With PDRN Versus Fractional CO₂ Laser (PDRN CO2 LASER)

March 11, 2026 updated by: Omnia Tarek Hosni, Misr University for Science and Technology

Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With Polydeoxyribonucleotide (PDRN) Versus Fractional CO₂ Laser: A Randomized Controlled Clinical Study

Facial scars are frequently deemed unpleasant and can profoundly impact a patient's psychological health. This study compares the effectiveness, safety, and capacity to speed up scar healing in the maxillofacial region between fractional carbon dioxide (CO₂) laser therapy alone and polydeoxyribonucleotide (PDRN) combined with CO₂ laser therapy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Giza, Egypt
        • Recruiting
        • Misr University for Science and Technology
        • Contact:
        • Principal Investigator:
          • Omnia Tarek Hosni, Bachelor Degree

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age Limitations: Participants must be between 18 and 50 years of age.
  • Recently cut wounds or surgical scars from about (1-6 months).
  • Consent to Participate: Willingness to provide informed consent and engage in all aspects of the study.

Exclusion Criteria:

  • Pregnancy or breastfeeding at the time of study.
  • Known allergy to PDRN.

  • Medication use that could affect wound healing or inflammation, such as:

    • Isotretinoin.
    • Anticancer drugs.
    • High-dose corticosteroids.
    • Anticoagulants.
  • Uncontrolled medical diseases (e.g., unstable diabetes, cardiac conditions).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Fractional Carbon Dioxide Laser Combined with Polydeoxyribonucleotide (PDRN)
includes patients who will be enrolled for PDRN injection into the surgical scar
Drug: Polydeoxyribonucleotide
intralesional PDRN injections
Device: Fractional CO2 laser assisted PDT
Fractional carbon dioxide (CO₂) laser therapy for facial scars
Other Names:
  • co2 laser
Placebo Comparator: Fractional CO₂ laser therapy with placebo saline injection
includes patients who will be enrolled for placebo saline injection into the surgical scar
Device: Fractional CO2 laser assisted PDT
Fractional carbon dioxide (CO₂) laser therapy for facial scars
Other Names:
  • co2 laser

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vancouver Scar Scale
Time Frame: 4 months

The study used the standard Vancouver Scar Scale, which evaluates four characteristics of scars:

Total Score Range: 0 (normal skin) to 13 (severe hypertrophic scar)
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Misr University for Science and Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2026

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

March 11, 2026

First Submitted That Met QC Criteria

March 11, 2026

First Posted (Actual)

March 16, 2026

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 11, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 011 (Nahrain Medical Research Collective (NMRC))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Facial Scarring

Clinical Trials on Polydeoxyribonucleotide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe